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Mitochondria carry maternally inherited genetic material, called the mitochondrial genome (mtDNA),
which can be defined as the 25th human chromosome. The chromosome-centric Human Proteome
Project (c-HPP) has initially focused its activities addressing the characterization and quantification of
the nuclear encoded proteins. Following the last International HUPO Congress in Boston (September
2012) it was clear that however small the mitochondrial chromosome is, it plays an important role in
many biological and physiopathological functions. Mutations in the mtDNA have been shown to be
associated with dozens of unexplained disorders and the information contained in the mtDNA should
be of major relevance to the understanding of many human diseases. Within this paper we describe the
Italian initiative of the Human Proteome Project dedicated to mitochondria as part of both programs:
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chromosome-centric (c-HPP) and Biology/Disease (B/D-HPP). The mt-HPP has finally shifted the
attention of the HUPO community outside the nuclear chromosomes with the general purpose to
highlight the mitochondrial processes influencing the human health. Following this vision and
considering the large interest and evidence collected on the non-Mendelian heredity of Homo sapiens
associated with mt-chromosome and with the microbial commensal ecosystem constituting our
organism we may speculate that this program will represent an initial step toward other HPP initiatives
focusing on human phenotypic heredity.
1. Introduction
Mitochondria are essential organelles for cell life and death. A
plethora of pathologies, including neurodegenerative diseases,
cancer, diabetes but also aging, have been reported to be
associated with mitochondrial dysfunction. Mitochondria carry
maternally inherited genetic material, called the mitochondrial
genome (mtDNA), which can be defined as the 25th human
chromosome. Mutations in the mtDNA have been shown to be
associated with dozens of unexplained disorders and the informa-
tion contained in the mtDNA should be of major relevance for the
understanding of many human diseases. Moreover, a systematic
investigation of the proteins encoded by the mtDNA (mtProteins)
and their relationships with nuclear Mendelian gene products will
significantly improve our understanding of these diseases.
The chromosome-centric Human Proteome Project (c-HPP)
started its activities pursuing the characterization of the
proteins encoded by the nuclear 24 chromosomes (see Fig. 1
for a list of countries and the chromosomes they are pursuing).1
However, many of these proteins, encoded at the nuclear level,
play important physiopathological functions in the mitochon-
dria and interact with other proteins that are encoded by the
mtDNA. The functional and pathological correlation of the
mtProteins with the nuclear encoded proteins (nProteins) is a
fundamental task of the Mitochondrial Proteome Initiative
(mt-HPP). Furthermore, the information collected in the
mt-HPP program will be compared to the information that will
be generated within the Biology/Disease Human Proteome
Project (B/D-HPP), which consists of the most recent initiatives
launched by the Human Proteome Organization (Fig. 2).2 An
integrated view of the molecular makeup of the human mito-
chondria will represent a strong base for studying the mito-
chondrial alterations which occur in many human diseases.
Within this article we present the concept and the mission
of mt-HPP, a new HUPO initiative led by the Italian Proteomics
Association (ItPA) focused on human mitochondrial proteins.
2. Mitochondrial basic biology and
chromosome coding
Mitochondria are cellular organelles delegated to the genera-
tion of energy through oxidative phosphorylation (OXPHOS),
although they are involved in many diﬀerent functions such as
pyruvate oxidation, the tricarboxylic acid cycle, and metabolism
of amino acids, fatty acids, and steroids. These tasks
are performed by mitochondrial structural and functional
specializations, which allow the spatial separation of diﬀerent
compartments. In fact, the two mitochondrial membranes
(outer and inner) delimit two chemically diﬀerent spaces, the
intermembrane space and the mitochondrial matrix. The inner
membrane accommodates five multimeric protein complexes,
NADH dehydrogenase–ubiquinone oxidoreductase (complex I),
succinate dehydrogenase–ubiquinone oxidoreductase (complex II),
ubiquinone–cytochrome c oxidoreductase (complex III), cyto-
chrome c oxidase (complex IV), ATP synthase (complex V) and
two small electron carriers (ubiquinone and cytochrome c)
which altogether constitute the respiratory chain. The role of
the respiratory chain is to produce metabolic energy in the form
of ATP, by using the reducing substrates NADH and FADH2
produced in intermediary metabolism pathways. Two coordi-
nated processes make this possible: (1) oxidation of substrates
in which the transfer of electrons from reduced dinucleotides
to the ultimate acceptor, the molecular oxygen, is coupled to
the active extrusion of protons in the intermembrane space by
complexes I, III, and IV; and (2) phosphorylation of ADP plus
phosphate in which the proton electrochemical gradient
generated across the inner membrane is used by the ATPase
(complex V) to drive back the protons in the matrix, thus
providing the energy to support ATP synthesis.
Because mtDNA has only 37 genes, most of the approxi-
mately 900 gene products reported so far in the organelle are
encoded by nuclear DNA (nDNA) and imported from the
cytoplasm.3 An example is provided by the 53 human gene
products (i.e., the mitochondrial carrier family) that transport
metabolites, nucleotides and cofactors across the inner mito-
chondrial membrane providing a link between enzymatic reac-
tions/metabolic pathways located in the mitochondria and
other cellular compartments.4 Human mtDNA is a 16 569 bp,
double-stranded, circular molecule containing 37 genes (Fig. 1).
Among them, 24 are needed for mtDNA translation (2 ribosomal
RNAs [rRNAs] and 22 transfer RNAs [tRNAs]), while 13 encode
subunits of the respiratory chain: seven subunits of complex I
(ND1, 2, 3, 4, 4L, 5, and 6), one subunit of complex III (CYB),
three subunits of cytochrome c oxidase (CO1, 2, and 3), and two
subunits of ATP synthase (ATP6 and 8). Mitochondrial genetics
diﬀers from Mendelian genetics in three major aspects:
maternal inheritance, heteroplasmy, and mitotic segregation.
Nuclear gene mutations can aﬀect not only mtDNA structure
(deletions) and content (depletions), but also the assembly
and maintenance of respiratory chain complexes, causing
secondary respiratory chain defects. These mutations aﬀect
many mitochondrial functions and can have secondary eﬀects
on oxidative phosphorylation and other processes.
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Aside from providing the cell with most of its energy,
mitochondria buﬀer cytosolic calcium (Ca2+), generate and
control Reactive Oxygen Species (ROS) production and regulate
apoptosis through the mitochondrial Permeability Transition
Pore (mtPTP). Moreover, mitochondria regulate several signal-
ling cascades through ATP and acetyl-CoA production: ATP and
acetyl-CoA are co-reactants in the phosphorylation and acetyla-
tion pathways of histones as well as of many other proteins.5
Furthermore, mitochondrial metabolism regulates the redox
status of small molecules such as NADP/NADPH, glutathione
and other thiol/disulfide couples and, in this way, the activity of
several enzymes and transcription factors.
Optimal mitochondrial function is ensured by a quality-
control system tightly coupled to fusion and fission processes
(i.e.MFN2, OPA1 and DRP1 gene products).6 A huge decrease of
Mnf2 and Drp1 has been reported in old rat liver suggesting
age-correlated reduced mitochondrial dynamics in liver tissue.7
Several factors have been described to convert hormonal,
neuronal, environmental and metabolic stimuli into transcrip-
tional adaptations leading to enhanced mitochondrial turnover
and content. Modulation of mitochondrial content is exerted
through the orchestrated expression of nuclear and mito-
chondrial genomes. Although mitochondria do not contain
histones, mtDNA is coated by several proteins and packaged
into aggregates called nucleoids or mitochromosome. Among
these proteins, mitochondrial transcription factor A (TFAM) is
the most abundant. Similar to histones TFAM could be acety-
lated.8 Moreover, the presence of three sirtuins, SIRT3, 4 and 5,
NAD+-dependent protein deacetylase, which couple their bio-
chemical and biological functions to the organism’s energetic
state via their dependency on NAD+, have been reported. The
mitochondrial sirtuins act to control basic mitochondrial biol-
ogy, including energy production, metabolism, apoptosis, and
intracellular signalling.9 Cytosine methylation of mtDNA,
restricted to CpG dinucleotides, was reported in the mito-
chondria of several species. The mechanisms establishing
Fig. 1 Map of the mitochondrial DNA (mtDNA) and chromosome array of the nuclear DNA (nDNA). Human mtDNA codifies 2 ribosomal RNAs (12S and 16S), 22
transfer RNAs (amino acid symbols) and 13 protein subunits of the respiratory chain: seven subunits of complex I (ND1, 2, 3, 4, 4L, 5, and 6), one subunit of complex III
(CYB), three subunits of cytochrome c oxidase (CO1, 2, and 3), and two subunits of ATP synthase (ATP6 and 8). The remaining mitochondrial proteins are codified by
the nDNA. The panel shows some genes aﬀecting mitochondria-related diseases (in red) sorted by the chromosome location (1–22, X and Y). The nations or the
international consortia participating in c-HPP are indicated (three-letter country codes).
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and maintaining mtDNA methylation and the functional
significance of this modification in mtDNA are not known;
however, for this epigenetic modification a role in the regula-
tion of mitochondrial transcription has been hypothesized.10
In Table 1, the proteins encoded in the mtDNA are reported
together with the number of theoretical SRM proteotypic peptides
observed by diﬀerent MS platforms. However the number of
total mtProteins is relatively low, few proteotypic transitions
have been reported (ESI,† Table S1). Moreover, the distribution
of the peptide descriptors is not homogenous along the protein
sequences. As an example, we can evaluate the distribution of
proteotypic peptides for NADH-ubiquinone oxidoreductase
chain 1 (Fig. 3), taken from PeptideAtlas (www.peptideatlas.org),
where only the N-terminus and the C-terminus of the protein
are experimentally accessible by SRM. Such a distribution
matches the soluble domain of the protein sequence without
covering the trans-membrane region.
The development of novel strategies to extend region cover-
age is a key step for exploring potential modifications of
mtProteins and to correlate them to a specific function. Such
modifications have been recently explored in the NDUFS4
subunit of complex I of the mammalian respiratory chain
which has a conserved carboxy-terminus with a canonical
RVSTK phosphorylation site. Immunochemical analysis with
specific antibodies shows that the serine in this site of the
protein is natively present in complex I in both the phosphory-
lated and non-phosphorylated states.11
3. Mitochondria and disease
Almost 200 diﬀerent mutations of mtDNA have been reported
in man. Advances in genetics and cell biology have provided
valuable insights into the function of mitochondria and the
contribution of mitochondrial metabolism defects in human
diseases. mtDNA mutations are a primary cause and can be due
to inherited sequence changes in the mitochondrial genome
(i.e. deletions, rearrangements, point mutations). However,
mitochondrial-related diseases can be associated with several
primary genetic causes aﬀecting also the nuclear genome.
Some of these mutations are consistently associated with
specific phenotypes (e.g. parkin and PINK1 with Parkinson’s
disease, MFN2 with Charcot–Marie–Tooth disease type 2A, frataxin
with Friedreich’s ataxia and SLC25A20 encoding the carnitine/
acylcarnitine carrier (CAC) with CAC deficiency) (Table 2).
Several lines of evidence suggest that mitochondrial
dysfunction is an early event in most late-onset neurodegen-
erative diseases such as Parkinson’s and Alzheimer’s diseases,
etc. Several studies and reviews have reported that age-related,
mitochondria generated ROS are factors in the development
and progression of late-onset neurodegenerative diseases.12–18
The fascinating possibility to delay the progression of these
diseases may involve the reformatting of mitochondrial func-
tions before symptoms appear.19 In this respect, the under-
standing of the interactions of both the mtDNA and the
respiratory chain complexes with nitric oxide (NO) appears
crucial. NO is released enzymatically in the body and also at
Fig. 2 The position of the mitochondrial Italian Human Proteome Project
Initiative (mt-HPP) in the Human Proteome Project (HPP). The verge diagram
shows how the mt-HPP is connected to both the investigative arms of HPP:
mt-HPP participates with the chromosome-centric HPP (c-HPP) in the character-
ization of mtDNA-encoded proteins, but it is also related to the other biology and
disease driven projects (B/D-HPP) being focused on the proteins involved in
mitochondria-associated diseases.
Table 1 Mitochondrial DNA genes
Gene name Protein name UniprotKB
Sequence
length (aa)
Distinct
peptides*
Total
observations*
Protein
coverage* (%)
Likely observable
sequence* (%)
MT-ND1 NADH-ubiquinone oxidoreductase chain 1 P03886 318 4 309 9.4 29.4
MT-ND2 NADH-ubiquinone oxidoreductase chain 2 P03891 347 1 102 2.5 6.1
MT-ND3 NADH-ubiquinone oxidoreductase chain 3 P03897 115 1 50 13.0 25.0
MT-ND4 NADH-ubiquinone oxidoreductase chain 4 P03905 459 4 101 12.4 43.5
MT-ND4L NADH-ubiquinone oxidoreductase chain 4L P03901 98 — — — —
MT-ND5 NADH-ubiquinone oxidoreductase chain 5 P03915 603 5 215 12.6 16.7
MT-ND6 NADH-ubiquinone oxidoreductase chain 6 P03923 174 1 2 8.0 21.5
MT-CYB Cytochrome b P00156 380 1 64 2.3 8.2
MT-CO1 Cytochrome c oxidase subunit 1 P00395 513 2 25 7.6 19.5
MT-CO2 Cytochrome c oxidase subunit 2 P00403 227 18 2326 63.8 81.4
MT-CO3 Cytochrome c oxidase subunit 3 P00414 261 2 3 8.8 42.5
MT-ATP6 ATP synthase subunit a P00846 226 1 150 4.4 10.3
MT-ATP8 ATP synthase protein 8 P03928 68 2 18 29.4 31.7
*Information obtained by PeptideAtlas (www.peptideatlas.org).
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the mitochondrial level by specific NO synthases (mtNOS);
moreover, the highly oxidizing peroxynitrite (reactive oxygen
and nitrogen species, RONS) is produced by the NO and the
superoxide ion, accounting for severe degradation of proteins
and DNA in the mitochondrion. Interestingly, carbon monoxide
and hydrogen sulfide have also been reported to crosstalk with
mitochondria controlling their function.20
A common involvement of mitochondria in the oxidant
imbalance was documented in fibromyalgia and chronic fati-
gue, two chronic pain syndromes with unknown etiology and
pathophysiology. Several groups of investigators suggested that
biochemical dysfunction in metabolism of ATP and OXPHOS
and consequent free radical production and oxidative stress
might play an important role in the pathophysiology of
CFS.21,22 On the other hand morphological and numerical
changes of mitochondria have been observed in skeletal muscle
from fibromyalgia patients23,24 along with reduced levels of
coenzyme Q10, a decrease in mitochondrial membrane
potential and an increase in levels of mitochondrial superoxide
in blood mononuclear cells.25 The study of mitochondrial
proteins, their characterization and involvement in these diseases
may contribute to the understanding of the pathophysiology of
fibromyalgia26 and chronic fatigue syndrome and allow us to
identify new therapeutic approaches.
Mitochondrial metabolism impairment may play a central
role in the pathophysiology of common chronic non-transmissible
diseases such as type 2 diabetes. Limited evidence is available
on the impact of active-foods and nutritional modulation
on mitochondria and lifespan regulation as much as on
the development of potential treatments for mitochondrial
dysfunction-related diseases. Dietary interventions, especially
caloric restriction, have been shown to improve the course of
chronic non-transmissible disorders and to extend life expec-
tancy; however, a subtle integrative model of mitochondrial
function is still not available.27
Mitochondria were first proposed to be relevant in cancer
by Otto Warburg who reported that cancer cells exhibited
‘‘aerobic-glycolysis’’.28 Although this aspect was originally inter-
preted as indicating that the function of mitochondria was
defective, we now understand that cancer cells are in an altered
metabolic state.29 The resurgence of interest in metabolism in
cancer cells has started to focus attention back on the mito-
chondria and there is increasing evidence that mutations in
mtDNA encoded genes can contribute to the development of
cancer.30 It is possible that such mutations provide metabolic
adaptivity to the cancer cells. A number of cancer-related
mitochondrial defects have been identified and described in
the literature. These defects include altered expression and
activity of respiratory chain subunits and glycolytic enzymes,
decreased oxidation of NADH-linked substrates, as well as
mtDNA mutations. However, DNA mutations aﬀecting mito-
chondrial function in cancer can also occur in nuclear
DNA genes, such as fumarate hydratase (FH) gene, which is
associated with a rare cancer syndrome, the hereditary
Fig. 3 The distribution of putative proteotypic peptides along the amino acid sequence of the ND1 subunit of complex I. A PeptideAtlas (www.peptideatlas.org)
elaboration on the availability of tryptic peptides for SRM quantitation of ND1 subunit of complex I. The four observed peptides match two short traits of the ND1
sequence with 9.4% total sequence coverage (upper and middle panels). The prediction of likely observable sequences indicates that the accessible regions are
restricted to the N- and C-termini of the amino acid chain (bottom panel).
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Table 2 Nuclear-encoded genes which aﬀect mitochondrial related diseases
Gene
name Location Protein name Disease OMIM
MFN2 1p36.22 Mitofusin-2 Charcot–Marie–Tooth disease, type 2A2 609 260
Hereditary motor and sensory neuropathy VI 601 152
COQ9 16q21 Ubiquinone biosynthesis protein COQ9 Coenzyme Q10 deficiency, primary, 5 614 654
ABC7 Xq13.3 ATP-binding cassette sub-family B member 7 Anemia, sideroblastic, with ataxia 301 310
FXN 9q21.11 Frataxin Friedreich ataxia 229 300
SPG7 16q24.3 Paraplegin Spastic paraplegia 7, autosomal recessive 607 259
OPA1 3q29 Dynamin-like 120 kDa protein Optic atrophy 1 165 500
Optic atrophy with or without deafness,
ophthalmoplegia, myopathy, ataxia, and neuropathy
125 250
PARK7 1p36.23 Protein DJ-1 Parkinson disease 7, autosomal recessive early-onset 606 324
PINK1 1p36.12 Serine/threonine-protein kinase PINK1 Parkinson disease 6, early onset 605 909
PARK2 6q26 E3 ubiquitin-protein ligase parkin Adenocarcinoma of lung, somatic 211 980
Adenocarcinoma, ovarian, somatic 167 000
Parkinson disease, juvenile, type 2 600 116
SLC25A20 3p21.31 Mitochondrial carnitine/acylcarnitine carrier
protein
Carnitine-acylcarnitine translocase deficiency 212 138
SLC25A4 4q35.1 ADP/ATP translocase 1 Cardiomyopathy, familial hypertrophic 192 600
Progressive external ophthalmoplegia with
mitochondrial DNA deletions 3
609 283
SLC25A3 12q23.1 Phosphate carrier protein Mitochondrial phosphate carrier deficiency 610 773
SLC25A15 13q14.11 Mitochondrial ornithine transporter 1 Hyperornithinemia–hyperammonemia–
homocitrullinemia syndrome
238 970
SLC25A22 11p15.5 Mitochondrial glutamate carrier 1 Epileptic encephalopathy, early infantile, 3 609 304
SLC25A19 17q25.1 Mitochondrial thiamine pyrophosphate carrier Microcephaly, Amish type 607 196
Thiamine metabolism dysfunction syndrome 4
(progressive polyneuropathy type)
613 710
SLC25A12 2q31.1 Calcium-binding mitochondrial carrier protein
Aralar1
Hypomyelination, global cerebral 612 949
SLC25A13 7q21.3 Calcium-binding mitochondrial carrier protein
Aralar2
Citrullinemia, adult-onset type II 603 471
Citrullinemia, type II, neonatal-onset 605 814
NDUFS1 2q33.3 NADH-ubiquinone oxidoreductase 75 kDa
subunit
Mitochondrial complex I deficiency 252 010
NDUFS2 1q23.3 NADH dehydrogenase [ubiquinone] iron–sulfur
protein 2
Mitochondrial complex I deficiency 252 010
NDUFS3 11p11.2 NADH dehydrogenase [ubiquinone] iron–sulfur
protein 3
Leigh syndrome 256 000
NDUFS4 5q11.2 NADH dehydrogenase [ubiquinone] iron–sulfur
protein 4
Leigh syndrome 256 000
Mitochondrial complex I deficiency 252 010
NDUFS6 5p15.33 NADH dehydrogenase [ubiquinone] iron–sulfur
protein 6
Mitochondrial complex I deficiency 252 010
NDUFS7 19p13.3 NADH dehydrogenase [ubiquinone] iron–sulfur
protein 7
Leigh syndrome 256 000
NDUFS8 11q13.2 NADH dehydrogenase [ubiquinone] iron–sulfur
protein 8
Leigh syndrome 256 000
NDUFV1 11q13.2 NADH dehydrogenase [ubiquinone] flavoprotein 1 Mitochondrial complex I deficiency 252 010
NDUFV2 18p11.22 NADH dehydrogenase [ubiquinone] flavoprotein 2 Mitochondrial complex I deficiency 252 010
NDUFA1 Xq24 NADH dehydrogenase [ubiquinone] 1 alpha
subcomplex subunit 1
Mitochondrial complex I deficiency 252 010
NDUFA2 5q31.3 NADH dehydrogenase [ubiquinone] 1 alpha
subcomplex subunit 2
Leigh syndrome 256 000
NDUFA11 19p13.3 NADH dehydrogenase [ubiquinone] 1 alpha
subcomplex subunit 11
Mitochondrial complex I deficiency 252 010
NDUFAF1 15q15.1 Complex I intermediate-associated protein 30 Mitochondrial complex I deficiency 252 010
NDUFAF2 5q12.1 Mimitin Leigh syndrome 256 000
Mitochondrial complex I deficiency 252 010
SDHA 5p15.33 Succinate dehydrogenase [ubiquinone]
flavoprotein subunit
Cardiomyopathy, dilated, 1GG 613 642
Leigh syndrome 256 000
Mitochondrial respiratory chain complex II deficiency 252 011
Paragangliomas 5 614 165
SDHB 1p36.13 Succinate dehydrogenase [ubiquinone]
iron–sulfur subunit
Cowden-like syndrome 612 359
Gastrointestinal stromal tumor 606 764
Paraganglioma and gastric stromal sarcoma 606 864
Paragangliomas 4 115 310
Pheochromocytoma 171 300
SDHC 1q23.3 Succinate dehydrogenase cytochrome b560
subunit
Gastrointestinal stromal tumor 606 764
Paraganglioma and gastric stromal sarcoma 606 864
Paragangliomas 3 605 373
SDHD 11q23.1 Succinate dehydrogenase [ubiquinone]
cytochrome b small subunit
Carcinoid tumors, intestinal 114 900
Cowden-like syndrome 612 359
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leiomyomatosis and renal cell carcinoma (HLRCC).31 While
there are many reports of these phenomena, the mechanisms
responsible for the initiation and evolution of mtDNA muta-
tions, and their roles in the development of cancer, drug
resistance, and disease progression still remain unknown.
Thus, a thorough proteomic investigation of mitochondria in
diﬀerent cancer cell models will be instrumental to identify
novel protein targets/pathways relevant to define these aspects.
This approach will eventually allow us to draw unique gene
expression stress signatures leading to these adaptive
responses, which potentially may provide molecular markers
for treatment modality.
4. Further implications for human health
DNA mutations in the mitochondrial genome are the major
contributing factors of aging and senescence. Accumulation of
somatic mtDNA defects is responsible for ROS production and
oxidative damage in aged tissues, even more in the presence of
NO excess. Over-expression of mitochondrially targeted anti-
oxidants, such as catalase, manganese superoxide dismutase,
and methionine sulfoxide reductase, decreases oxidative damage
and extends healthy lifespan. Mitochondria, in fact, utilize more
than 90% of cellular oxygen and during normal respiration
0.1–0.2% of ROS are formed as by-products. ROS produce damage
primarily to mtDNA, lipids and proteins, which lie in proximity to
the main cellular ROS producer, the mitochondrial electron
transport chain. The oxidative damage of mitochondrial lipids
and proteins as well as the gradual accumulation of mtDNA
mutations over time result in defective electron transport and
increase of RONS production. Mitochondria, on the other hand,
are endowed with several defense mechanisms, including RONS
scavengers, such as glutathione binding NO and complex IV
oxidizing NO to nitrite, and ROS converting enzymes, like
manganese superoxide dismutase and peroxiredoxin 3.32
Interaction with other species could modulate the metabolic
life of mitochondria. Microbiomes or single species of bacteria
through the production of toxins (or eﬀectors) and metabolites
which specifically target mitochondria could modulate this
organelle during an infection33 or during the normal life.34
Furthermore, it has been well documented that mitochondrial
metabolism could also be regulated by bacterial presence.
There are indeed some compounds of bacterial origin, which
can interfere with mitochondria enhancing or reducing their
activity. Probiotics, like lactic acid bacteria (Lactobacillus and
Bifidobacterium genera, LAB), are found in the normal gut
microflora of mammals and humans. There is evidence that
LAB can modulate through mitochondria the apoptosis of
cardiomyocytes.35 Thus, a topic that will be explored is the
relation of mitochondrial protein expression in immuno-
competent cells (i.e. lymphocytes) during chronic infection.
Chronic infection induces hyperactivation of the immune
system and increases exposure to ROS. These phenomena
could contribute to alter mitochondrial metabolism and
protein expression. For instance, the changes induced by HIV
infection on mtDNA have already been well documented.36 To
date, however, a systematic investigation of the mitochondrial
proteome in immune cells during chronic infection has not
been pursued. Because of the documented interaction between
bacterial symbionts, human cells and mitochondrial protein
expression, we can speculate on the development of a complete
investigation which takes into account the overall proteomes of
the superorganism. The superorganism is an organism resulting
from symbiotic interactions among human and bacterial cells
which contribute to regulate the overall protein expression and
metabolism of every human tissue.
Table 2 (continued )
Gene
name Location Protein name Disease OMIM
Paraganglioma and gastric stromal sarcoma 606 864
Paragangliomas 1, with or without deafness 168 000
Pheochromocytoma 171 300
BCS1L 2q35 Mitochondrial chaperone BCS1 Bjornstad syndrome 262 000
GRACILE syndrome 603 358
Leigh syndrome 256 000
Mitochondrial complex III deficiency 124 000
SURF1 9q34.2 Surfeit locus protein 1 Leigh syndrome, due to COX deficiency 256 000
SCO1 17p13.1 Protein SCO1 homolog Hepatic failure, early onset, and neurologic
disorder
SCO2 22q13.33 Protein SCO2 homolog Cardioencephalomyopathy, fatal infantile,
due to COX deficiency
604 377
COX10 17p12 Protoheme IX farnesyltransferase Encephalopathy, progressive mitochondrial, with
proximal renal tubulopathy due to COX deficiency
COX15 10q24.2 Cytochrome c oxidase assembly protein COX15
homolog
Cardiomyopathy, hypertrophic, early-onset fatal
Leigh syndrome due to COX deficiency
256 000
COX6B1 19q13.12 Cytochrome c oxidase subunit 6B1 Cytochrome c oxidase deficiency 220 110
FASTKD2 2q33.3 FAST kinase domain-containing protein 2 Mitochondrial complex IV deficiency 220 110
ETHE1 19q13.31 Protein ETHE1 Ethylmalonic encephalopathy 602 473
ATPAF2 17p11.2 ATP synthase mitochondrial F1 complex
assembly factor 2
Mitochondrial complex V (ATP synthase)
deficiency, nuclear type 1
604 273
ATP5E 20q13.32 ATP synthase subunit epsilon Mitochondrial complex V (ATP synthase)
deficiency, nuclear type 3
614 053
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5. The framework for the Mitochondrial
Proteome Initiative (mt-HPP)
The Mitochondrial Proteome Initiative (mt-HPP) has been
initiated by the Italian Proteomics Association (ItPA) executive
board with the aim to integrate the chromosome-centric
Human Proteome Project (c-HPP) with the characterization of
the mitochondrial DNA-encoded proteins. Moreover the devel-
opment of such a program is directly providing the framework
for the integration with the Biology and Disease Program of the
Human Proteome Project (B/D-HPP).
Herein, we indicate the overall key milestones which we
intend to pursue following the mt-HPP initiative.
Key milestones will include the following tasks:
(1) Definition of Proteomics-based technologies for the
identification and quantitation of mtDNA-encoded proteins
(mtProteins). This task will include an eﬀort to develop separa-
tion, SRM strategies and top-down investigations to tackle:
(i) Single nucleotide polymorphism variants
(ii) Post-translational modifications
(iii) mtProtein biomarkers in specific diseases
(2) Definition of a comprehensive protein interaction map
for the mtProteins. This task will include the following items:
(i) mtProtein–mtProtein interaction and oligomeric status
in the membrane
(ii) mtProtein–nProtein (nuclear encoded protein)
interaction map
(iii) mtProtein–p/scProtein (pathogen/symbiont coded
protein) interaction map
(3) Definition of an integrated OMICS model with a parti-
cular focus on metabolite fingerprint – the proteome map. This
action will include:
(i) Correlation of mtProtein profiles, metabolite finger-
prints and RNA patterns
(ii) Correlation of nProtein localized in the mitochondria,
metabolite fingerprints and RNA patterns
(iii) Correlation of mtProtein and nProtein localized in
the mitochondria profiles with ionomics.
A detailed description of the specific project plans and their
associated methodologies will follow the kick-oﬀ meeting of the
first project proposals which will be held in Padua (June 18th–
21st, 2013) during the next Italian Proteomics Association
National Congress.
6. Future perspectives
Since the launching of the mt-HPP initiative, this has collected
the spontaneous adhesion of many Italian scientists engaged in
Italy and abroad in the investigation of structure–function
relationships of the mitochondrial proteins and their physio-
logical/pathological implications for cellular metabolism. The
wide participation leads us to extend our field of interest to all
the proteins operating in the mitochondrion, thus including
the nuclear DNA-encoded proteins involved in mitochondrial
processes which have a relevant impact on human health. In a
future perspective we wish to draw into the initiative a larger
number of contributors looking with special attention over the
national borders in accordance with the international connotation
of the HPP.
Mitochondrial proteins are involved in a broad range of
pathologies, therefore the mt-HPP oﬀers the valued opportu-
nities to cooperate with diﬀerent Biology and Disease driven
Projects (B/D-HPP) launched by HUPO (e.g. cancers and
diabetes). Moreover, we consider particularly relevant the devel-
opment of partnerships with the HUPO initiatives devoted to
specific diseases or organs such as the Human Brain Proteome
Project (HBPP) and the initiative on Model Organism Proteomes
(iMOP). The HBPP workgroup shares common objectives as a
deeper understanding of proteomemodifications underlying the
neurodegenerative diseases and aging or the identification of
prognostic and diagnostic biomarkers. The Initiative on Model
Organism Proteomes (iMOP) has a fundamental role given the
possibility to compare the proteomics data, pathways and
mechanisms conserved between models and humans.
mt-HPP has finally shifted the attention of the HUPO c-HPP
community outside the nuclear chromosome by proposing and
pursuing the specific aim to characterize and quantify the
mtProteins, with the general purpose to highlight the mito-
chondrial processes influencing human health. Following this
vision and considering the large interest and evidence collected
over the non-Mendelian heredity of Homo sapiens associated
with mt-chromosome and with the microbial commensal
consortia constituting our organism we may speculate that
the next initiative of HPP will be focused on the proteome
encoded by the chromosome of the human symbiotic micro-
organism community.
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